Our and previously reported results [15, 20] demonstrate that intracerebroventricular ERT can have a significant impact on the disease course of CLN2 disease, as well as potentially other neurodegenerative lysosomal storage disorders, which is a breakthrough in the treatment of these severe disorders. Here, TPP1 is linked to lysosomal storage disease.